Robert Ho Net Worth

The estimated Net Worth of Robert Ho is at least $570 Tisíc dollars as of 16 March 2021. Mr Ho owns over 25,000 units of Neoleukin Therapeutics stock worth over $97,720 and over the last 5 years he sold NLTX stock worth over $0. In addition, he makes $472,290 as Chief Financial Officer at Neoleukin Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Ho NLTX stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Neoleukin Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of NLTX stock worth $87,250 on 16 March 2021.

The largest trade he's ever made was exercising 25,000 units of Neoleukin Therapeutics stock on 16 March 2021 worth over $87,250. On average, Mr trades about 5,000 units every 0 days since 2020. As of 16 March 2021 he still owns at least 28,000 units of Neoleukin Therapeutics stock.

You can see the complete history of Mr Ho stock trades at the bottom of the page.

Mr. Robert Ho biography

Robert Ho is the Chief Financial Officer at Neoleukin Therapeutics.

What is the salary of Mr Ho?

As the Chief Financial Officer of Neoleukin Therapeutics, the total compensation of Mr Ho at Neoleukin Therapeutics is $472,290. There are 2 executives at Neoleukin Therapeutics getting paid more, with Jonathan Drachman having the highest compensation of $3,823,040.

How old is Mr Ho?

Mr Ho is 45, he's been the Chief Financial Officer of Neoleukin Therapeutics since . There are 7 older and 4 younger executives at Neoleukin Therapeutics. The oldest executive at Neoleukin Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director.

What's Mr Ho's mailing address?

Robert's mailing address filed with the SEC is C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE, WA, 98102.

Insiders trading at Neoleukin Therapeutics

Over the last 5 years, insiders at Neoleukin Therapeutics have traded over $425,653 worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth $38,477,971 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... a Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $593,084. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth $1,462,619.

What does Neoleukin Therapeutics do?

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Complete history of Mr Ho stock trades at Neoleukin Therapeutics

Neoleukin Therapeutics executives and stock owners

Neoleukin Therapeutics executives and other stock owners filed with the SEC include:

• Jonathan Drachman,
  President, Chief Executive Officer, Director
• Dr. Jonathan G. Drachman,
  CEO, Pres & Director
• Robert Ho,
  Chief Financial Officer
• Todd Simpson,
  Independent Chairman of the Board
• Lewis Williams,
  Independent Director
• Sarah Noonberg,
  Independent Director
• M. Cantey Boyd,
  Independent Director
• Erin Lavelle,
  Director
• Martin Babler,
  Director
• Samantha Willing,
  Vice President - People
• Leslie Aberman,
  Vice President - Legal Affairs and Intellectual Property
• Robert Ho,
  Chief Financial Officer, Secretary
• Dr. Bill Arthur,
  VP & Head of Research
• Dr. Priti Patel M.D., M.S.,
  Chief Medical Officer
• Umut Ulge,
  VP of Clinical Devel.
• Dr. Carl Walkey Ph.D.,
  Sr. VP of Corp. Devel.
• Holly K. Vance,
  Gen. Counsel
• Dr. David Baker,
  Co-founder & Member of Scientific Advisory Board
• Kamran Alam,
  Sr. Strategic Advisor
• Group, Llc Green Jeremy Red...,
  
• Sean Michael Smith,
  Interim CFO, Prin Acct Off
• Holly Vance,
  General Counsel
• Sean P. Nolan,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Priti Patel,
  
• Carl Walkey,
  Senior Vice President
• Bros. Advisors Lp667, L.P.B...,
  
• Erin M. Lavelle,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Donna Cochener,
  General Counsel, SVP Legal
• Rohan Palekar,
  Director